* Skye Bioscience Inc reported a quarterly adjusted loss of 10 cents per share for the quarter ended September 30. The mean expectation of six analysts for the quarter was for a loss of 25 cents per share. Wall Street expected results to range from -34 cents to -17 cents per share.
* Reported revenue was zero; analysts expected zero.
* Skye Bioscience Inc's reported EPS for the quarter was a loss of 10 cents.
* The company reported a quarterly loss of $3.9 million.
* Skye Bioscience Inc shares had risen by 37.3% this quarter and gained 97.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 19.4% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Skye Bioscience Inc is $19.00 This summary was machine generated from LSEG data November 8 at 05:11 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.25 -0.10 Beat
Jun. 30 2024 -0.19 -0.20 Missed
Mar. 31 2024 -0.16 -0.18 Missed
Dec. 31 2023 -0.38 -0.63 Missed
Comments